Re: Reconsidering Prostate Cancer Mortality - The Future of PSA Screening: The future of PSA screening by reconsidering prostate cancer mortality

Affiliations

¹ Department of Surgical and Diagnostic Integrated Sciences (DISC), Division of Urology, University of Genoa, Genoa, Italy. Electronic address: marco.borghesi@unige.it.
² Department of Surgical and Diagnostic Integrated Sciences (DISC), Division of Urology, University of Genoa, Genoa, Italy. Electronic address: nazarenoroberto.suardi@unige.it.
³ Department of Surgical and Diagnostic Integrated Sciences (DISC), Division of Urology, University of Genoa, Genoa, Italy. Electronic address: carlo-terrone@med.uniupo.it.

Comment

Marco Borghesi et al. Eur Urol. 2020 Dec.

. 2020 Dec;78(6):929.

doi: 10.1016/j.eururo.2020.06.028. Epub 2020 Jul 1.

¹ Department of Surgical and Diagnostic Integrated Sciences (DISC), Division of Urology, University of Genoa, Genoa, Italy. Electronic address: marco.borghesi@unige.it.
² Department of Surgical and Diagnostic Integrated Sciences (DISC), Division of Urology, University of Genoa, Genoa, Italy. Electronic address: nazarenoroberto.suardi@unige.it.
³ Department of Surgical and Diagnostic Integrated Sciences (DISC), Division of Urology, University of Genoa, Genoa, Italy. Electronic address: carlo-terrone@med.uniupo.it.

No abstract available

Comment on

Reconsidering Prostate Cancer Mortality - The Future of PSA Screening.
Welch HG, Albertsen PC. Welch HG, et al. N Engl J Med. 2020 Apr 16;382(16):1557-1563. doi: 10.1056/NEJMms1914228. N Engl J Med. 2020. PMID: 32294352 No abstract available.